Caris Life Sciences,�Inc. (CAI)
(Real Time Quote from BATS)
$32.21 USD
-0.73 (-2.22%)
Updated Sep 23, 2025 03:30 PM ET
3-Hold of 5 3
D Value D Growth C Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CAI 32.21 -0.73(-2.22%)
Will CAI be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CAI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CAI
TEM Gains Validation for PurIST Amid Evolving Cancer Care Landscape
CAI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for CAI
Is CAI showing upside potential? Crossed Above 50 Day Moving Average shows up after advancing 1.1%
CIBC Launches $450 Million Capital Notes Offering
Fell Below 50 Day Moving Average appears for CAI after 2.54% move
The technical outlook for CAI is unchanged after it falls 0.3% on September 18
Caris Life Sciences: Impressive Growth, But Lock-Up Expiry Looms